Document is current

Article History

Received: 17 April 2023

Accepted: 1 November 2023

First Online: 10 November 2023

Declarations

:

: The study was conducted in compliance with the approval granted by the University of New South Wales Human Research Committee (HC190049) which granted a waiver of informed consent for the study as the data were deidentified and analysed retrospectively and anonymously. The subsequent reciprocal approval (2022-03715) was granted by the Human Research Ethics Committee of Edith Cowan University via an exempt pathway. The study was also approved (R257) by the Research Governance Office of HammondCare. A data custodian at DSA handled the data according to ethical principles set out by the Declaration of Helsinki, and the National Health and Medical Research Council’s National Statement on Ethical Conduct in Human Research.

: Not applicable.

: The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: MA, DW and TM are staff members of The Dementia Centre, HammondCare; a research, education, and consultancy arm of HammondCare, an independent Christian charity which auspices the DSA programs – the Dementia Behavior Management Advisory Service (DBMAS) and the Severe Behavior Response Team (SBRT). MA is one of the originators of the PainChek instrument, which is marketed by PainChek Ltd. (ASX: PCK). He is also a shareholder of PainChek Ltd. He previously held the position of Senior Research Scientist (October 2018–May 2020) at PainChek Ltd. He had a granted patent titled ‘A pain assessment method and system; PCT/AU2015/000501’ in Australia, China, Japan, and the United States, which was assigned to PainChek Ltd. The other authors declare that they have no competing interests.